Metrion Biosciences Unveils Breakthrough NaV1.9 Screening Assay to Accelerate Non-Opioid Pain Therapeutics Development
核心洞察
Metrion Biosciences (搜索) has launched a validated high-throughput NaV1.9 (搜索) screening assay, overcoming traditional limitations in targeting this crucial pain (搜索) signaling channel.
The new assay completes Metrion's comprehensive suite of pain (搜索)-related sodium channel (搜索) assays (NaV1.1 (搜索)-NaV1.9 (搜索)), enabling more efficient selectivity profiling and accelerated lead optimization.
Developed using stable CHO cell lines with both human and rat clones, the assay provides critical insights into species selectivity that could advance the development of novel non-opioid pain therapeutics (搜索).
Metrion Biosciences (搜索) has launched a validated high-throughput screening assay for NaV1.9 (搜索), a voltage-gated sodium channel (搜索) critical in pain (搜索) signaling pathways. This development represents a significant advancement in pain research, as it addresses longstanding challenges that have hindered the development of non-opioid pain therapeutics (搜索) targeting this channel.
NaV1.9 (搜索) is selectively expressed in peripheral sensory neurons and plays a key role in pain (搜索) signaling mechanisms. Human genetic studies have established its significance, with mutations in NaV1.9 linked to both severe pain conditions and pain insensitivity. Despite its recognized potential as a non-opioid therapeutic target, research progress has been limited by difficulties in developing stable heterologous expression systems capable of reliably studying the channel.
"The availability of effective assays to study the NaV1.9 (搜索) sodium channel (搜索) has been a major stumbling block that has held back development of the next generation of non-opioid pain therapeutics (搜索)," explained Dr. Eddy Stevens, Chief Scientific Officer at Metrion Biosciences (搜索).
Technical Innovations in the NaV1.9 Assay
The newly developed assay leverages Metrion's decade-plus expertise in electrophysiology and has been designed using a stable, validated CHO cell line (搜索). Key technical features include:
- In-house optimization for high reproducibility and low variability
- Availability in both human- and rat-derived clones to provide insights into species selectivity
- Compatibility with automated patch clamp technology using the Qube 384 platform for high-throughput screening
- Integration with manual clamp-based mechanistic and translational assays for deeper pharmacological insights
This technical approach enables researchers to overcome traditional limitations of NaV1.9 (搜索) screening and generate reproducible, decision-ready data that can accelerate drug discovery efforts.
Comprehensive Pain Channel Screening Portfolio
The NaV1.9 (搜索) assay completes Metrion's full suite of pain (搜索)-related sodium channel (搜索) assays, providing comprehensive selectivity profiling across NaV1.1 (搜索) to NaV1.9. This complete portfolio represents a significant resource for pharmaceutical companies and research institutions working on novel pain therapeutics.
Metrion's integrated offering now includes:
- Selectivity profiling across all pain-relevant sodium channels
- Off-target counter screens for pain-related ion channel targets
- CiPA panel for cardiac safety risk assessment
- Support services for hit-to-lead and lead optimization phases
This comprehensive approach streamlines compound evaluation and has the potential to significantly reduce project timelines in pain (搜索) therapeutic development.
Implications for Non-Opioid Pain Therapeutics
The development of this assay comes at a critical time in pain (搜索) research, as the need for effective non-opioid alternatives continues to grow amid ongoing concerns about opioid addiction and side effects. NaV1.9 (搜索) represents a promising target for developing more selective pain medications with potentially fewer side effects than current treatments.
By facilitating streamlined compound evaluation and accelerated lead optimization, Metrion's new screening capabilities could help bring novel pain (搜索) therapeutics to market more rapidly and cost-effectively. The ability to conduct high-throughput screening against NaV1.9 (搜索) may unlock new chemical matter and therapeutic approaches that were previously inaccessible due to technical limitations.
Strategic Significance for Metrion Biosciences
For Metrion Biosciences (搜索), a specialist preclinical contract research organization based in Cambridge, UK, this launch represents a strategic milestone that reinforces its position as a leader in ion channel drug discovery services.
"This important launch represents a major milestone for Metrion, a testament to the dedication and knowledge of our team and reinforces our position as leading the field in ion channel drug discovery," noted Dr. Stevens.
The company's unique combination of sodium channel (搜索) expertise, high-throughput screening solutions, and specialized research services positions it as a valuable partner for pharmaceutical companies seeking to develop next-generation pain (搜索) therapeutics targeting the NaV family of channels.
Future Directions in Pain Research
The availability of this new screening tool may catalyze renewed interest in NaV1.9 (搜索) as a therapeutic target. With the technical barriers to studying this channel now significantly reduced, researchers can more effectively explore its pharmacology and develop compounds with improved selectivity profiles.
As the field of pain (搜索) research continues to seek alternatives to opioid-based treatments, technologies that enable more precise targeting of pain pathways, such as Metrion's NaV1.9 (搜索) assay, will play an increasingly important role in addressing unmet medical needs in pain management.